Last reviewed · How we verify
Gadoquatrane (BAY1747846)
Gadoquatrane (BAY1747846) is a Gadolinium-based contrast agent Small molecule drug developed by Bayer. It is currently in Phase 3 development for Magnetic resonance imaging (MRI) contrast enhancement for vascular and tissue imaging.
Gadoquatrane is a gadolinium-based contrast agent designed for magnetic resonance imaging (MRI) that provides enhanced visualization of blood vessels and tissues.
Gadoquatrane is a gadolinium-based contrast agent designed for magnetic resonance imaging (MRI) that provides enhanced visualization of blood vessels and tissues. Used for Magnetic resonance imaging (MRI) contrast enhancement for vascular and tissue imaging.
At a glance
| Generic name | Gadoquatrane (BAY1747846) |
|---|---|
| Sponsor | Bayer |
| Drug class | Gadolinium-based contrast agent |
| Target | Water proton relaxation (T1 relaxation enhancement) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | Phase 3 |
Mechanism of action
Gadoquatrane (BAY1747846) is a macrocyclic gadolinium chelate contrast agent that works by shortening the T1 relaxation time of water protons in tissues, thereby increasing signal intensity on T1-weighted MRI images. It is formulated as a blood pool agent intended to provide prolonged vascular enhancement, enabling improved imaging of perfusion and vascular anatomy.
Approved indications
- Magnetic resonance imaging (MRI) contrast enhancement for vascular and tissue imaging
Common side effects
- Gadolinium retention in tissues
- Nephrogenic systemic fibrosis (NSF) risk in renal impairment
- Injection site reactions
Key clinical trials
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) (PHASE3)
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems (PHASE3)
- A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric) (PHASE3)
- A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants (PHASE1)
- Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gadoquatrane (BAY1747846) CI brief — competitive landscape report
- Gadoquatrane (BAY1747846) updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Gadoquatrane (BAY1747846)
What is Gadoquatrane (BAY1747846)?
How does Gadoquatrane (BAY1747846) work?
What is Gadoquatrane (BAY1747846) used for?
Who makes Gadoquatrane (BAY1747846)?
What drug class is Gadoquatrane (BAY1747846) in?
What development phase is Gadoquatrane (BAY1747846) in?
What are the side effects of Gadoquatrane (BAY1747846)?
What does Gadoquatrane (BAY1747846) target?
Related
- Drug class: All Gadolinium-based contrast agent drugs
- Target: All drugs targeting Water proton relaxation (T1 relaxation enhancement)
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Diagnostic Imaging
- Indication: Drugs for Magnetic resonance imaging (MRI) contrast enhancement for vascular and tissue imaging
- Compare: Gadoquatrane (BAY1747846) vs similar drugs
- Pricing: Gadoquatrane (BAY1747846) cost, discount & access